Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

被引：0
|
作者：
Gizem Oner
Semen Önder
Hüseyin Karatay
Naziye Ak
Mustafa Tükenmez
Mahmut Müslümanoğlu
Abdullah İğci
Ahmet Dincçağ
Vahit Özmen
Adnan Aydiner
Ekrem Yavuz
Neslihan Cabioğlu
机构：
[1] Istanbul University,Department of General Surgery, Istanbul Faculty of Medicine
[2] Antwerp University Hospital,Multidisciplinary Oncologic Centre Antwerp (MOCA)
[3] University of Antwerp,Center for Oncological Research (CORE)
[4] Istanbul University,Department of Pathology, Istanbul Faculty of Medicine
[5] Istanbul University,Department of Medical Oncology, Institute of Oncology
来源：
World Journal of Surgical Oncology | / 19卷
关键词：
Triple-negative breast cancer; PD-L1 expression; Prognosis; Neoadjuvant chemotherapy response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Effect of PD-1 and PD-L1 in the tumor microenvironment on overall survival of triple-negative breast cancer patients
    Linnaus, M. E.
    Kosiorek, H.
    Barrett, M. T.
    Dueck, A.
    Anderson, K. S.
    Ocal, I. T.
    McCullough, A. E.
    Annamalai, L.
    Yearley, J. H.
    Pockaj, B. A.
    CANCER RESEARCH, 2017, 77
  • [32] PD1, PD-L1 and PD-L2 mRNA Expression in triple-negative Breast Cancer
    Schueler, K.
    Bethmann, D.
    Staege, M.
    Kantelhardt, J. E.
    Thomssen, C.
    Vetter, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (06) : E24 - E24
  • [33] Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
    Sung Gwe Ahn
    Seon-Kyu Kim
    Jonathan H. Shepherd
    Yoon Jin Cha
    Soong June Bae
    Chungyeul Kim
    Joon Jeong
    Charles M. Perou
    Breast Cancer Research and Treatment, 2021, 188 : 165 - 178
  • [34] Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor
    Basik, Mark
    Roseshter, Talia
    Klemantovich, Anna
    Cavallone, Luca
    Aguilar-Mahecha, Adriana
    Lafleur, Josiane
    Lan, Cathy
    Elebute, Oluwadara
    Jenna, Sarah
    Boileau, Jean-Francois
    Pelmus, Manuela
    CANCER RESEARCH, 2024, 84 (09)
  • [35] Clinical Implications of Transcriptomic Changes After Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
    Orozco, Javier I. J.
    Grumley, Janie G.
    Matsuba, Chikako
    Manughian-Peter, Ayla O.
    Chang, Shu-Ching
    Chang, Grace
    Gago, Francisco E.
    Salomon, Matthew P.
    Marzese, Diego M.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (10) : 3185 - 3193
  • [36] Clinical Implications of Transcriptomic Changes After Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
    Javier I. J. Orozco
    Janie G. Grumley
    Chikako Matsuba
    Ayla O. Manughian-Peter
    Shu-Ching Chang
    Grace Chang
    Francisco E. Gago
    Matthew P. Salomon
    Diego M. Marzese
    Annals of Surgical Oncology, 2019, 26 : 3185 - 3193
  • [37] Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
    Ahn, Sung Gwe
    Kim, Seon-Kyu
    Shepherd, Jonathan H.
    Cha, Yoon Jin
    Bae, Soong June
    Kim, Chungyeul
    Jeong, Joon
    Perou, Charles M.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (01) : 165 - 178
  • [38] Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
    Sun, Woo Young
    Lee, Yu Kyung
    Koo, Ja Seung
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [39] Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
    Kim, H. -M.
    Sun, W. -Y.
    Lee, Y. -K.
    Koo, J. -S.
    VIRCHOWS ARCHIV, 2016, 469 : S55 - S55
  • [40] Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
    Woo Young Sun
    Yu Kyung Lee
    Ja Seung Koo
    Journal of Translational Medicine, 14
12345